

XJTLU, University of Liverpool open joint centre for pharmacology & therapeutics in China

10 November 2022 | News

The Joint Centre's research and development activities are expected to benefit both Suzhou – which boasts over 400 high-tech biopharmaceutical startups in its BioBAY industrial park and aims to be the "Pharmacy Valley of China" – and the Liverpool City Region

Xi'an Jiaotong-Liverpool University (XJTLU) and the University of Liverpool are opening a Joint Centre for Pharmacology and Therapeutics in China.

The Joint Centre, a Sino-UK collaborative venture, will engage top scientists from both countries to enhance research on disease mechanisms and develop novel drugs for the treatment of modern-day diseases.

As a global research hub for interdisciplinary and innovative research, the Joint Centre will offer a unique platform for knowledge exchange and talent cultivation between academic laboratories and their industrial and clinical partners in basic and clinical research on drug safety science, immuno-pharmacology, precision medicine, nanomedicine and regulatory science.

Members of the Joint Centre include senior researchers from XJTLU; the Department of Pharmacology and Therapeutics from the University of Liverpool, an established world leader in pharmacology and toxicology research; Hengrui Pharmaceutical Co. (Shanghai), a pharmaceutical giant in China; and Suzhou Guangji Psychiatric Hospital.

The Joint Centre will harness state-of-the-art equipment and facilities in pharmaceutical sciences, molecular biology, chemistry, and environmental sciences along with activities funded by the government, the private sector and the pharmaceutical industry.